Study identifier:D5180C00037
ClinicalTrials.gov identifier:NCT05274815
EudraCT identifier:2021-005457-85
CTIS identifier:N/A
A Multicentre, Single-arm, Phase 3b Efficacy and Safety Study of Tezepelumab 210 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Participants with Severe Asthma on High-dose Inhaled Corticosteroid plus Long-acting β2 Agonist and Long-term Oral Corticosteroid Therapy (WAYFINDER)
asthma
Phase 3
No
-
All
306
Interventional
18 Years - 80 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Jul 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Tezepelumab Tezepelumab subcutaneous injection | - |